Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients by de Winter, Brenda C. M. et al.
Pharmacokinetic role of protein binding
of mycophenolic acid and its glucuronide metabolite
in renal transplant recipients
Brenda C. M. de Winter • Teun van Gelder •
Ferdi Sombogaard • Leslie M. Shaw •
Reinier M. van Hest • Ron A. A. Mathot
Received: 1 July 2009/Accepted: 25 October 2009/Published online: 11 November 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract Mycophenolic acid (MPA), the active compound of mycophenolate
mofetil (MMF), is used to prevent graft rejection in renal transplant recipients. MPA
is glucuronidated to the metabolite MPAG, which exhibits enterohepatic recircu-
lation (EHC). MPA binds for 97% and MPAG binds for 82% to plasma proteins.
Low plasma albumin concentrations, impaired renal function and coadministration
of cyclosporine have been reported to be associated with increased clearance of
MPA. The aim of the study was to develop a population pharmacokinetic model
describing the relationship between MMF dose and total MPA (tMPA), unbound
MPA (fMPA), total MPAG (tMPAG) and unbound MPAG (fMPAG). In this model
the correlation between pharmacokinetic parameters and renal function, plasma
albumin concentrations and cotreatment with cyclosporine was quantiﬁed. tMPA,
fMPA, tMPAG and fMPAG concentration–time proﬁles of renal transplant recipi-
ents cotreated with cyclosporine (n = 48) and tacrolimus (n = 45) were analyzed
using NONMEM. A 2- and 1-compartment model were used to describe the
pharmacokinetics of fMPA and fMPAG. The central compartments of fMPA and
fMPAG were connected with an albumin compartment allowing competitive
binding (bMPA and bMPAG). tMPA and tMPAG were modeled as the sum of the
bound and unbound concentrations. EHC was modeled by transport of fMPAG to a
separate gallbladder compartment. This transport was decreased in case of
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DOI 10.1007/s10928-009-9136-6cyclosporine cotreatment (P\0.001). In the model, clearance of fMPAG decreased
when creatinine clearance (CrCL) was reduced (P\0.001), and albumin concen-
tration was correlated with the maximum number of binding sites available for MPA
and MPAG (P\0.001). In patients with impaired renal function cotreated with
cyclosporine the model adequately described that increasing fMPAG concentrations
decreased tMPA AUC due to displacement of MPA from its binding sites. The
accumulated MPAG could also be reconverted to MPA by the EHC, which caused
increased tMPA AUC in patients cotreated with tacrolimus. Changes in CrCL had
hardly any effect on fMPA exposure. A decrease in plasma albumin concentration
from 0.6 to 0.4 mmol/l resulted in ca. 38% reduction of tMPA AUC, whereas no
reduction in fMPA AUC was seen. In conclusion, a pharmacokinetic model has
been developed which describes the relationship between dose and both total and
free MPA exposure. The model adequately describes the inﬂuence of renal function,
plasma albumin and cyclosporine co-medication on MPA exposure. Changes in
protein binding due to altered renal function or plasma albumin concentrations
inﬂuence tMPA exposure, whereas fMPA exposure is hardly affected.
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List of symbols
MPA Mycophenolic acid
MPAG Mycophenolic acid glucuronide
t Total concentration
f Unbound concentration
TLAG Lag-time
ka First order absorption rate constant
Vc Central volume
CL Clearance
Vp Peripheral volume
Q Intercompartmental clearance
knm Rate constant between compartment n and m
BMAX Maximum number of protein binding sites
TGB Time of gallbladder emptying
DGB Duration of gallbladder emptying
IPV Interpatient variability
CrCL Creatinine clearance
CsA Cyclosporine
Introduction
Mycophenolate mofetil (MMF) is currently the most prescribed immunosuppressive
agent in renal transplant recipients to prevent graft rejection [1]. After oral
administration the prodrug MMF is rapidly hydrolyzed to the active agent
mycophenolic acid (MPA). The majority of MPA is metabolized to the inactive
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1237-O-mycophenolic acid glucuronide (MPAG), which exhibits enterohepatic recir-
culation (EHC). MPA is a selective, reversible inhibitor of inosine monophosphate
dehydrogenase (IMPDH). IMPDH has an important role in the de novo purine
synthesis in T and B lymphocytes [2]. Inhibition of this pathway causes
immunosuppression, contributing to the prevention of graft rejection. Although
introduced as a ﬁxed-dose drug, debate has emerged with respect to the potential
contribution of therapeutic drug monitoring (TDM) of MPA area under the total
plasma concentration time curve (AUC0–12)[ 3–6]. The target range for total MPA
(tMPA) AUC0–12 in renal transplant recipients cotreated with cyclosporine is
30–60 mg h/l [7].
MPA is a highly protein bound drug, with a bound fraction of approximately
97%, which binds reversibly to serum albumin [8, 9]. The free fraction is thought to
be responsible for the immunosuppressive effect of MPA [8, 9]. The main
metabolite MPAG is approximately 82% protein bound [9]. Low plasma albumin
concentrations and impaired renal function are associated with an increased
clearance of tMPA and with a decreased AUC0–12 of tMPA [10]. The effect of
impaired renal function on unbound MPA (fMPA) plasma concentrations is
however not clear: some studies have reported an increase in fMPA AUC0–12
[11–15], whereas in other studies unbound exposure was unchanged [16, 17].
Coadministration of the calcineurin inhibitor cyclosporine inﬂuences MPA
pharmacokinetics. In renal transplant recipients, signiﬁcantly increased tMPA
clearance and decreased tMPA AUC0–12 occurs with cyclosporine coadministration
compared with tacrolimus coadministration [18, 19]. This effect can be explained by
reduced EHC of MPAG in case of cyclosporine cotreatment due to inhibition of the
multi-drug resistance-associated protein 2 (MRP2) enzyme [20].
Decreased tMPA exposure correlates with a higher risk for acute rejection
[21–23], whereas an increase in unbound MPA exposure may produce hematolog-
ical toxicity and infections [23, 24]. On the basis of these data it is unclear whether a
decreased total MPA AUC0–12, caused by impaired renal function or low albumin
concentrations, should be corrected with an increase in MMF dose, as the patient
subsequently may be at risk for adverse events.
The aim of this study was to develop a population pharmacokinetic model, which
describes the relationship between MMF dose and both total and unbound plasma
concentrations of MPA and MPAG. Using this model, it will be investigated how
renal function, plasma albumin and cotreatment with cyclosporine inﬂuence the
pharmacokinetics of tMPA and fMPA. The developed model may provide insight in
the necessity to adjust the MMF dose in situations of impaired renal function and
low albumin concentrations.
Methods
Patients
Pharmacokinetic data from two previously performed studies were used for the
current analysis. In the ﬁrst trial, a randomized concentration controlled trial
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123(RCCT) [25], de novo renal transplant recipients were divided into three MPA AUC
target groups. All patients in this study were cotreated with cyclosporine and
corticosteroids as concomitant immunosuppressive therapy. In this study, tMPA,
fMPA and total MPAG (tMPAG) concentrations were measured at day 3, 7, 11, 21,
28, 56, 84, 112 and 140 after transplantation. On days 3, 7 and 11 posttransplan-
tation, sample times were predose and 0.33, 0.66, 1.25, 2, 6, 8 and 12 h after oral
intake of MMF. On the remaining occasions, sample times were predose and 0.33,
0.66, 1.25 and 2 h postdose. Concentrations were measured using a validated high-
performance liquid chromatography (HPLC) method [26]. MMF dose was adjusted
based on these measurements. From a subset of 88 patients fMPA concentrations
were measured on one or two of the nine occasions, which were nominally day 11
and/or day 140. These fMPA concentrations were analyzed using a validated
ultraﬁltration procedure [27].
In the second trial, the IMPDH-activity study [28], de novo renal transplant
recipients started with 1000 mg MMF twice daily, combined with tacrolimus and
corticosteroids. MMF dose was adjusted based on clinical evaluations. In the
IMPDH-activity study tMPA, fMPA, tMPAG and unbound MPAG (fMPAG)
concentrations were measured at day 6, 21, 49 and 140 after transplantation. On day
6, samples were taken predose and 0.5, 1, 2, 6 and 12 h postdose. On the remaining
occasions, sample times were predose and 0.5 and 2 h after oral intake of MMF.
Concentrations were measured using a validated liquid chromatography-tandem
mass spectrometry (LC-MS/MS) method [29]. For the determination of unbound
plasma concentrations of MPA and MPAG, plasma was ultraﬁltrated ﬁrst. A
detailed description of these studies was published previously [25, 28].
Pharmacokinetic analysis
Basic model
The MMF dose and analysed MPA and MPAG concentrations were converted to
molar equivalents by dividing them by their molecular weight (MMF 433.5 g/mol;
MPA 320.3 g/mol; MPAG 496.5 g/mol). The data of both studies were simulta-
neously ﬁtted using the nonlinear mixed-effect modeling software program
NONMEM (version VI, level 2.0; Globomax LLC, Ellicott City, MD, USA). The
ﬁrst-order (FO) method was used throughout to ﬁt the logarithmically transformed
concentration–time data, because of the high computational intensity of the ﬁrst
order conditional estimate method.
The minimum value of objective function (OFV) was used as a criterion for
model selection. If the difference between two nested models was larger than the
critical value from a V
2 distribution with degrees of freedom equal to the difference
in the number of estimated parameters, the models were signiﬁcantly different from
each other. A decrease in OFV[10.83 showed a signiﬁcant improvement of a
nested model with one degree of freedom of P\0.001. Model adequacy was
further evaluated by using various residual plots (‘‘goodness-of-ﬁt’’ plots) and
values of random effects variances. To assess the graphical goodness of ﬁt,
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123extensive plotting was available via Xpose [30], a purpose built set of subroutines in
S-plus (version 6.1; Insightful Corp, Seattle, WA, USA).
A compartmental pharmacokinetic model was developed for fMPA and fMPAG.
Several structural models were tested. Models with 1 or 2 compartments were
evaluated, as well as models with and without absorption lag-time (TLAG).
Furthermore, it was evaluated whether absorption was best described as a zero-order
or ﬁrst-order process. Pharmacokinetic parameters were estimated in terms of
central and peripheral volume of distribution (V), clearance (CL), and intercom-
partmental clearance (Q). Because bioavailability (F) could not be quantiﬁed, V, CL
and Q values correspond to the ratios V/F, CL/F, and Q/F. Addition of interpatient
variability (IPV), described using an exponential error model, was evaluated for
each pharmacokinetic parameter. The covariance between values for IPV was
estimated using a variance–covariance matrix. Residual variability between
observed and predicted MPA plasma concentrations was described using an
additional error model for logarithmically transformed data.
Protein bound MPA (bMPA) and bound MPAG (bMPAG) were described by
addition of a protein binding compartment, containing a maximum number of
binding sites (Bmax) at which MPA and MPAG could bind (Fig. 1). In this model
MPA and MPAG were allowed to bind competitively with the protein binding sites,
and replace each other from these binding sites as described by
dA1
dt
¼  ka   A1 ð1Þ
dA2
dt
¼ ka   A1   k25   A2   k23   A2 þ k32   A3
  k24   A2   BMAX   A4   A6 ðÞ þ k24   A4 þ k72   A7 ð2Þ
dA3
dt
¼ k23   A2   k32   A3 ð3Þ
dA4
dt
¼ k24   A2   BMAX   A4   A6 ðÞ   k42   A4 ð4Þ
dA5
dt
¼ k25   A2   k56   A5   BMAX   A4   A6 ðÞ
þ k65   A6   k50   A5   k57   A5 ð5Þ
dA6
dt
¼ k56   A5   BMAX   A4   A6 ðÞ   k65   A6 ð6Þ
dA7
dt
¼ k57   A5   k72   A7; ð7Þ
where An represents the amount of a substance in the nth compartment and knm
represents the rate constant for transport between compartment n and compartment
m. Values for the dissociation constant (KD) can be calculated from this differential
equations by dividing k42 by k24 for MPA and k65 by k56 for MPAG. The
concentrations of tMPA and tMPAG were modeled as the sum of the unbound and
bound concentrations.
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123Furthermore, to describe the EHC of the drug a gallbladder compartment was
added, which is responsible for the reconversion of fMPAG into fMPA (Fig. 1). It
was evaluated whether transport of fMPAG to the gallbladder was best described as
a zero-order or ﬁrst-order process. The gallbladder emptied into the central
compartment of fMPA at a certain time point postdose [31].
Covariate model
Finally, to explain IPV, relationships were investigated between pharmacokinetic
parameters and patient characteristics known to inﬂuence MPA pharmacokinetics.
Covariates assessed were renal function, plasma albumin concentration, and
cyclosporine comedication. Renal function was tested by calculation of the
creatinine clearance (CrCL) according to Cockcroft and Gault [32]. Continuous
covariates, such as albumin concentration (Alb) were modeled by using an
exponential model, as shown in Eq. 8.
hi ¼ hpop   Alb=0:5 ðÞ
halb; ð8Þ
where hi represents the parameter for ith individual, hpop is the population value
with Alb = 0.5 mmol/l, and halb is an exponent determining the shape of the cor-
relation. Categorical variables, such as cyclosporine comedication, were modeled
proportionally as shown in Eq. 9.
fMPA
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fMPAG
VC
fMPA
VC
BMAX 
Gut
2 3
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1
4/6
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k56 
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k24 
CLMPA
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k65 
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k57 
k72 
 TGB 
7
Fig. 1 Graphical representation of the ﬁnal model. MPA and MPAG bind competitively to the protein
binding sites. fMPA is cleared to fMPAG by ﬁrst order elimination. fMPAG is eliminated by a ﬁrst order
process (CLMPAG), or undergoes enterohepatic recirculation via the gall bladder compartment
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123hi ¼ hpop   hCsA
CsA; ð9Þ
where CsA = 1 for patients cotreated with cyclosporine and CsA = 0 for patients
not cotreated with cyclosporine, and hCsA represents the fractional change of the
parameter in patients cotreated with cyclosporine.
Model validation
The ﬁnal model was validated by a visual predictive check [33]. Data sets (n = 50)
were simulated from the original data set using the ﬁnal model. Per time point, the
dose-corrected median simulated concentrations plus 95-percentile intervals were
compared graphically with the observed concentrations for fMPA, tMPA, fMPAG,
and tMPAG separately. The dataset was analyzed separately for different categories
of the covariates included in the ﬁnal model.
Simulation study
The ﬁnal model was used to examine the impact of changes in covariates on the
pharmacokinetics of MPA and MPAG. Simulations were performed to demonstrate
how the disposition of MPA and MPAG was affected by clinically relevant changes
in renal function, plasma albumin concentration and cyclosporine comedication.
Simulations were performed with the ﬁnal model for 50 patients treated with 1 g
MMF twice daily and cyclosporine, and for 50 patients treated with 1 g MMF twice
daily and tacrolimus. CrCL was initially set on 50 ml/min, and was decreased to 30
and 10 ml/min. The initial value for albumin concentration was 0.5 mmol/l, which
was varied to 0.4 and 0.6 mmol/l. Changes in concentration–time proﬁles, free
fraction and AUC0–12 values of fMPA, tMPA, fMPAG and tMPAG were assessed.
Results
Patients
The data set contained 489 tMPA, 489 fMPA, 488 tMPAG, and 210 fMPAG plasma
concentrations obtained from 75 patients cotreated with cyclosporine or tacrolimus.
Each patient participated in one or two pharmacokinetic assessments at different
time points after transplantation. In total, 93 concentration–time proﬁles were used
for the analysis. Patient characteristics are described in Table 1.
Pharmacokinetic analysis
Compartmental model with protein binding
The ﬁnal model is shown in Fig. 1, corresponding typical population pharmaco-
kinetic estimates are summarized in Table 2. The standard errors of the estimated
parameters could not be obtained due to rounding errors of the ﬁnal run. The
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123pharmacokinetics of fMPA were described with a two-compartment model,
containing a central- and peripheral volume of distribution. fMPA from the central
compartment bound to the protein binding sites. The number of binding sites
(BMAX) was limited, which resulted in a saturable binding process. The pharma-
cokinetics of fMPAG were modeled with one, central compartment. From this
compartment, fMPAG bound to the same binding sites as fMPA, which resulted in
competitive binding. Due to this competition MPA and MPAG were able to displace
each other from the protein binding sites. Inclusion of the competitive binding
between MPA and MPAG signiﬁcantly improved the model compared to the model
without competition (DOFV =- 37). The protein binding and unbinding rate
constants of fMPA (k24 and k42) and fMPAG (k56 and k65) provide information on
the afﬁnity of both substances to the protein binding sites, which is higher for fMPA
(KD = 1100 lmol) than for fMPAG (KD = 7000 lmol). The interpatient variabil-
ity (IPV) in protein binding was described for BMAX using an exponential error
model.
Enterohepatic recirculation
The EHC was modeled by using a gallbladder compartment (Fig. 1, compartment
7). Transport of fMPAG from the central compartment to the gallbladder
compartment was characterized using the ﬁrst order rate constant k57. Emptying
Table 1 Patient characteristics
Cotreatment Cyclosporine
(n = 48 proﬁles)
Tacrolimus
(n = 45 proﬁles)
Gender (male/female)
a 30/17 18/10
Age (years)
a 51 (21–70) 53 (19–76)
Weight (kg)
a 67 (42–99) 78 (44–113)
Number of patients with DGF
a 41 1
Number of diabetic patients pretransplantation
a 22
Time after transplantation (days) 11 (7–155) 11 (4–115)
Plasma albumin (mmol/l) 0.51 (0.38–0.61) 0.51 (0.35–0.68)
Creatinine clearance (ml/min)
b 44 (8–107) 45 (8–154)
Heamoglobine (mmol Fe/l) 9.6 (6.9–13.0) 8.0 (4.2–13.0)
ASAT (U/l) 15 (6–50) 19 (6–236)
ALAT (U/l) 20 (7–155) 27 (7–534)
MMF dose (mg bid) 1350 (400–2200) 1000 (500–1500)
CNI daily dose (mg) 512.5 (250–1125) 8 (1–20)
CNI predose concentration (lg/l) 267.5 (21.0–619.1) 10.0 (1.5–30.0)
Parameters are presented as median (range) of all proﬁles, for patients treated with the calcineurin
inhibitors (CNI) cyclosporine and tacrolimus. DGF delayed graft function, ASAT aspartate aminotrans-
ferase, ALAT alanine transaminase, MMF mycophenolate mofetil
a parameters for all patients, of which some participated in two pharmacokinetic assessments
b calculated with Cockcroft & Gault-formula
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123of the gallbladder into the central compartment of fMPA occurred at a certain time
point (TGB) with rate constant k72 and duration DGB. Unfortunately, insufﬁcient data
were collected between 4 and 10 h postdose, the period at which the gallbladder is
expected to empty. As a result, the parameters describing the gallbladder emptying,
DGB and k72, were ﬁxed at 1 h and 10 h
-1. IPV was described with an additional
error model for TGB and with an exponential error model for k57. However, the IPV
of k57 had to be ﬁxed at 71%, to prevent variability on EHC to take on extreme
values. This value was based on the variance in EHC from 10 to 60% as described in
literature [9]. In comparison with a model without EHC (k57 = 0h
-1), addition of
the EHC signiﬁcantly improved the model (DOFV =- 43).
Covariate analysis
Decreased plasma albumin concentrations are known to be associated with reduced
protein binding of MPA [34]. Inclusion of plasma albumin concentration as
Table 2 Parameter estimates of
the pharmacokinetic model
a The parameter is ﬁxed at this
value
Parameter Value IPV (%)
TLAG (h) 0.231 161
ka (h
-1) 4.00
a
Vc fMPA (l) 189 116
CL fMPA (l/h) 747 97
Vp fMPA (l) 34300
Q fMPA (l/h) 2010
k24 (h
-1 lmol
-1) 0.153
BMAX (lmol) 35100 48
k42 (h
-1) 169
Vc fMPAG (l) 8.56
k56 (h
-1 lmol
-1) 0.0133
k65 (h
-1) 93.1
CL fMPAG (l/h) 4.75 106
TGB (h) 7.90 141
a
DGB (h) 1.00
a
k72 (h
-1) 10.0
a
k57 (h
-1) 0.0796 71
a
Residual variability
Additive error tMPA (mmol/l) 0.52
Additive error fMPA (mmol/l) 0.993
Additive error tMPAG (mmol/l) 0.186
Additive error fMPAG (mmol/l) 0.551
Covariate effects
CrCL on CL fMPAG 1.36
Albumine on BMAX 1.39
CsA on k57 0.002
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123covariate of BMAX (Eq. 3) signiﬁcantly improved the model (DOFV =- 26). The
IPV of fMPA CL, fMPAG CL and BMAX decreased slightly with 1, 6 and 1%,
respectively. A decrease in albumin from 0.6 to 0.4 mmol/l resulted in a decrease in
the number of binding sites from 45200 to 25700 lmol, as is graphically shown in
Fig. 2a.
Impaired renal function reduced renal clearance of MPAG [35]. In the present
study, a signiﬁcant correlation was observed between CrCL and fMPAG CL.
Introduction of CrCL improved the goodness of the ﬁt (DOFV =- 48). The IPV of
fMPA CL, fMPAG CL and BMAX decreased with 25, 57 and 17%, respectively. A
decrease in CrCL from 45 to 25 ml/min resulted in a decrease from 4.75 to 2.14 l/h
in clearance of fMPAG (Fig. 2b). No correlation was seen between CrCL and
fMPA CL.
Cyclosporine decreases the EHC of MPAG by inhibition of MRP2 [20]. In the
present study, implementation of cyclosporine as covariate on k57 signiﬁcantly
improved the model (DOFV =- 17). In patients cotreated with cyclosporine k56 is
very small with a value of 0.000159 h
-1 compared to 0.0796 h
-1 in patients
cotreated with tacrolimus. Inclusion of cyclosporine as a covariate on fMPA
clearance did not signiﬁcantly improve the model further.
Evaluation of the ﬁnal model
The goodness-of-ﬁt plots (Fig. 3) of the ﬁnal model were evaluated for tMPA,
fMPA, tMPAG and fMPAG separately. The scatter plots of predicted and
individually predicted versus observed concentrations showed no structural bias,
except for a small underprediction of the maximum concentration of tMPA and
fMPA. The weighted residuals exhibited a homogeneous distribution over the whole
sampling period (data not shown).
Fig. 2 Correlation of pharmacokinetic parameters versus covariate effects for a the number of protein
binding sites (BMAX) and plasma albumin concentration, and b fMPAG clearance and creatinine
clearance (CrCL). The line represents the estimated correlation between the pharmacokinetic parameter
and the covariate
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results are presented separately for patients cotreated with cyclosporine and
tacrolimus. Good agreement between the simulated and observed concentrations
was apparent at all sampling time points. However, there seemed to be a small
underprediction of the maximum tMPA and fMPA concentration. The visual
predictive check was performed separately for patients with CrCL\30 ml/min,
CrCL 30–50 ml/min and CrCL[50 ml/min as well as for patients with albumin
concentrations\0.5 and[0.5 mmol/l. The results of these visual predictive checks
on these selections gave similar results (data not shown).
Simulations
The pharmacokinetic proﬁles of tMPA, fMPA, tMPAG and fMPAG were simulated
for 50 renal transplant recipients receiving 1 g MMF twice daily using the ﬁnal
model. Covariate effects were set at typical values: plasma albumin concentration
0.5 mmol/l, CrCL 50 ml/min and comedication was cyclosporine or tacrolimus.
Subsequently, the effect of a change in plasma albumin concentration or CrCL was
evaluated.
A decrease in plasma albumin concentrations from 0.6 to 0.4 mmol/l, resulted in
decreased tMPA concentrations, whereas the effect on fMPA, tMPAG and fMPAG
concentrations was small (Fig. 5). The free fraction of both, MPA and MPAG,
almost doubled when albumin concentrations decreased from 0.6 to 0.4 mmol/l
(Fig. 6). This effect was larger for patients cotreated with cyclosporine (MPA:
2.4–5.3%, MPAG: 13.7–26.1%) than for patients cotreated with tacrolimus (MPA:
2.7–4.1%, MPAG: 14.9–21.3%). Furthermore, tMPA AUC0–12 values were
decreased in patients with low albumin concentrations (Fig. 7). A decrease in
albumin concentrations from 0.6 to 0.4 mmol/l, resulted in a decrease in mean
tMPA AUC from 30.1 to 17.7 mg h/l in patients cotreated with cyclosporine and
from 31.1 to 20.4 mg h/l in patients cotreated with tacrolimus. Consequently, a
decrease in albumin concentrations may cause a major underexposure to tMPA, as
the lower limit of the therapeutic window of tMPA AUC is 30 mg h/l. The exposure
to fMPA, tMPAG and fMPAG remained however stable, as indicated by Fig. 7b–d.
A decrease in renal function, characterized by a change in CrCL from 50 to
10 ml/min, had a large impact on the MPAG concentrations (Fig. 8). Both, tMPAG
and fMPAG concentrations increased, especially in patients cotreated with
cyclosporine. The changes in the concentration–time proﬁles of tMPA and fMPA
were small. A slight difference was seen at the end of the curve, where the
tacrolimus cotreated patients showed a higher EHC with impaired renal function
(Fig. 8e–f). This was caused by increased concentrations of fMPAG. The latter
undergoes EHC and is subsequently converted to MPA. tMPAG and fMPAG AUC
values were higher in patients with impaired renal function (Fig. 9). Corresponding
AUC values for tMPAG increased from 831 to 3794 mg h/l for patients cotreated
with cyclosporine and from 723 to 2647 mg h/l in patients with tacrolimus as
comedication. A decrease in CrCL from 50 to 10 ml/min resulted in increased
tMPA AUC in patients treated with tacrolimus (25.1–31.6 mg h/l). The opposite
effect was seen in patients treated with cyclosporine, in which tMPA AUC values
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123decreased from 23.9 to 21.5 mg h/l. Furthermore, fMPA AUC values remained
stable when renal function decreased, except for a small increase in fMPA AUC in
patients with CrCL of 10 ml/min and tacrolimus as comedication. The free fraction
of both MPA and MPAG increased in patients treated with cyclosporine (Fig. 10).
In tacrolimus treated patients no difference in free fraction was seen.
Discussion
A population pharmacokinetic model has been developed describing the protein
binding of MPA and the main metabolite MPAG for renal transplant recipients
receiving MMF and cyclosporine or tacrolimus (Fig. 1). The model provided a
semi-mechanistic explanation for increase of tMPA AUC and decrease in MPA free
fraction with increasing plasma albumin concentrations, renal function and
tacrolimus comedication. Simulations with the ﬁnal model can be used to provide
information about the effect of changes in albumin concentration or renal function
on tMPA and fMPA exposure.
Van Hest et al. [36] have previously published an empirical model describing the
protein binding of MPA. The current model is superior compared to the model of
van Hest et al. due to a more mechanism-based character of the model. Our model
described the protein binding process with a mass balance, based on physiological
processes. Mechanism-based models have much better properties for extrapolation
and prediction than empirical models [37].
In the current model, a competitive protein binding process was incorporated,
which described the interaction between MPA and MPAG. Increasing MPAG
concentrations were associated with increased free fractions of MPA and decreased
tMPA exposure. The model did not only describe the protein binding of MPA, but
also of the main metabolite MPAG. This was possible due to availability of fMPAG
concentration–time proﬁles, which were not available in the study of van Hest et al.
[36]. This addition allowed the protein binding process to be competitive between
MPA and MPAG.
Due to the complexity of the model, runtimes were very long (55 h for the ﬁnal
run). The ﬁnal run did not minimize successfully, due to rounding errors. As a
result, no standard errors of the parameter estimates were obtained. Other methods
to obtain information about the accuracy of the estimated parameters, like the
bootstrap resampling method and the jackknife, could not be used because of the
high computational intensity. However, the visual predictive check revealed a good
agreement between the simulated and observed concentrations at all sampling time
points, which indicate that the estimations of the pharmacokinetic parameters are
reasonable.
Fig. 3 Goodness-of-ﬁt plots of observed versus population predicted concentrations of a tMPA, b fMPA,
c tMPAG and d fMPAG, and observed versus individually predicted concentrations of e tMPA, f fMPA,
g tMPAG and h fMPAG. In the plots the line of identity is presented
b
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123The parameter BMAX is deﬁned as the maximum number of binding sites, to
which MPA and MPAG could bind. In theory, if the volume of plasma is roughly 3 l
and albumin (median: 510 lmol/l) has at least one binding site, then the total
number of binding sites in plasma should be C510 lmol/l 9 3l= 1530 lmol. In
the model, BMAX was estimated to be 35100 lmol, which is indeed larger than
1530 lmol. BMAX may be larger due to the fact that other proteins are also able to
Fig. 4 Visual predictive check of the comparison of median (dashed line) with 95-percentile interval
(solid lines) of 50 simulated data sets and the observed concentrations (dots). Concentrations are
corrected to an MMF dose of 1 g. Concentrations of a tMPA, b fMPA and c tMPAG for patients cotreated
with CsA, and d tMPA, e fMPA, f tMPAG and g fMPAG for patients cotreated with tacrolimus
b
Fig. 5 Inﬂuence of albumin concentrations on pharmacokinetic proﬁles. Median concentration–time
proﬁles of a tMPA, b fMPA, c tMPAG and d fMPAG in patients cotreated with CsA and concentration–
time proﬁles of e tMPA, f fMPA, g tMPAG and h fMPAG in patients cotreated with tacrolimus.
Concentration–time proﬁles were simulated for 50 patients with albumin concentrations of (ﬁlled
triangle) 0.4 mmol/l, (ﬁlled square) 0.5 mmol/l and (inverted triangle) 0.6 mmol/l
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123bind MPA or that each albumin molecule binds more than one MPA molecule.
Albumin is not conﬁned to plasma, but is continuously ﬁltered into interstitial ﬂuid,
and then returned to plasma via the thoracic duct. Albumin-bound drugs may
therefore be present in plasma, which contains 40% of albumin in the body, and in
interstitial ﬂuid, which contains the remaining 60% [38]. The latter may increase the
available number of binding sites as well.
In the model, the maximum number of binding sites available for MPA and
MPAG was restricted. The number of binding sites was correlated with the plasma
albumin concentration (Fig. 2a). A decrease in plasma albumin concentrations
resulted in less binding sites, causing an increase in the free fraction of MPA and
MPAG (Fig. 6), which has previously been reported [27, 34]. Due to this increase in
the free fraction, relatively more fMPA is available for clearance, resulting in a
decreased tMPA AUC (Fig. 7). However, the fMPA AUC was unaffected. The
Fig. 5 continued
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123phenomenon that free concentrations are independent of protein binding is
characteristic for drugs with a low extraction ratio [39]. The theoretical hepatic
extraction ratio of MPA is low (0.20) [40]. The simulations showed that changes in
albumin concentrations cause clinically relevant changes in tMPA AUC. A decrease
in albumin concentration from 0.6 to 0.4 mmol/l, resulted in a decrease in tMPA
AUC from 30.1 to 17.7 mg h/l in patients treated with cyclosporine and from 31.1
to 20.4 mg h/l in patients treated with tacrolimus. This implies that the tMPA AUC
could drop below the minimal effective value of 30 mg h/l and that the MMF dose
should be increased. This correlation between tMPA AUC and albumin concen-
trations is previously seen [34, 41]. In contrast, the fMPA AUC is almost unaffected
by the change in albumin concentration. A decrease in albumin concentration from
0.6 to 0.4 mmol/l resulted in an increase in fMPA AUC from 0.82 to 0.96 mg h/l for
patients cotreated with cyclosporine and from 0.84 to 0.93 mg h/l in patients
cotreated with tacrolimus.
The simulations showed that changes in CrCL have major effects on both
tMPAG and fMPAG exposure, but the effects on tMPA and fMPA exposure are
smaller. The CNI used in patients with impaired renal function leads to a differential
effect on tMPA and fMPA exposure. In case of cyclosporine, tMPA AUC decreased
and fMPA AUC remains the same. While in patients cotreated with tacrolimus, an
increased exposure to tMPA and a small increase in fMPA AUC was seen when
CrCL decreased to 10 ml/min. These opposing effects can be explained as follows:
In patients cotreated with tacrolimus, impaired renal function leads to accumulation
of MPAG (Fig. 2b). Accumulating MPAG concentrations result in increased
transport of MPAG to the gallbladder, leading to increased recirculation of MPAG
to MPA. Because of the extra recirculation, MPAG does not accumulate to an extent
where it can displace MPA from its protein binding sites. The result is increased
tMPA and fMPA (Fig. 9) due to extra recirculation and no change in unbound
fraction of MPA. In patients cotreated with cyclosporine, the accumulated MPAG
following impaired renal function can not be compensated for by increased
Fig. 6 Inﬂuence of albumin concentrations on the free fraction of a MPA and b MPAG. Free fractions
are presented as median and 95-percentile interval of 50 simulated patients cotreated with CsA (light)o r
tacrolimus (dark)
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123recirculation because cyclosporine minimizes EHC due to inhibition of MRP2 [20].
As a result MPAG displaces MPA from its protein binding sites, leading to an
increased unbound fraction of MPA (Fig. 10)[ 11, 35]. The increased fMPA
exposure is immediately compensated for by an increase in MPA glucuronidation as
MPA is a drug with a low extraction ratio [40]. The result is decreased tMPA
exposure, unchanged fMPA exposure and an increased MPA unbound fraction. The
simulated effects of CrCL on exposure to tMPA and fMPA in patients treated with
cyclosporine or tacrolimus are in accordance with previously published results [10,
31, 41, 42].
In vitro analysis showed that fMPA is the pharmacologically active compound,
which is responsible for inhibition of IMPDH [27]. Patients with elevated fMPA
exposure have an increased risk for leucopenia and infections [23, 24]. However,
although a relationship between fMPA exposure and the risk for acute rejection
Fig. 7 Inﬂuence of albumin concentrations on exposure of a tMPA, b fMPA, c tMPAG and d fMPAG
for patients cotreated with CsA (light) or tacrolimus (dark). AUCs are presented as mean and 95%
conﬁdence interval of 50 simulated patients
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123should be expected, it has not been demonstrated yet. On the other hand, a
correlation between tMPA exposure and the risk for acute rejection has been
reported [6, 21, 22]. Clearly, more information is needed about the relationship
between fMPA exposure and the risk for acute rejection and side effects to interpret
the clinical effect of changes in protein binding of MPA. In general, fMPA is
thought to be responsible for the immunosuppressive effect [8, 9, 27] and changes in
fMPA are supposed to be clinically relevant. Alterations in both albumin
concentrations and renal function have little effect on fMPA AUC and have
thereby little clinical relevance. However, special attention is necessary in patients
with impaired renal function cotreated with tacrolimus as the increased fMPAG can
cause elevated exposure to both tMPA and fMPA.
Fig. 8 Inﬂuence of creatinine clearance on pharmacokinetic proﬁles. Median concentration–time proﬁles
of a tMPA, b fMPA, c tMPAG, and d fMPAG in patients cotreated with CsA and concentration–time
proﬁles of e tMPA, f fMPA, g tMPAG, and h fMPAG in patients cotreated with tacrolimus.
Concentration–time proﬁles were simulated for 50 patients with CrCL of (ﬁlled triangle) 10 ml/min,
(ﬁlled square) 30 ml/min and (inverted triangle) 50 ml/min
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123In conclusion, this model describes the protein binding of both, MPA and its
main metabolite MPAG, and the relationship with albumin concentrations, renal
function and cyclosporine. When albumin concentrations decrease, tMPA exposure
decreases, but fMPA exposure remains unaffected. The increase in MPAG due to
impaired renal function is followed by a decrease in tMPA in patients cotreated with
cyclosporine and by an increase in tMPA in patients cotreated with tacrolimus.
Again, fMPA exposure is hardly affected by the changes in renal function. Changes
in protein binding, caused by alterations in albumin concentrations or renal function,
will not or hardly inﬂuence the exposure of a patient to the probably active agent
fMPA. Therefore, changes in protein binding have little clinical relevance if fMPA
is indeed the biologically active fraction.
Fig. 8 continued
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123Fig. 9 Inﬂuence of creatinine clearance on exposure of a tMPA, b fMPA, c tMPAG and d fMPAG for
patients cotreated with CsA (light) or tacrolimus (dark). AUCs are presented as mean and 95% conﬁdence
interval of 50 simulated patients
Fig. 10 Inﬂuence of CrCL on the free fraction of a MPA and b MPAG. Free fractions are presented as
median and 95-percentile interval of 50 simulated patients cotreated with CsA (light) or tacrolimus (dark)
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